Clinical Scorecard: Phase 1 Randomized Controlled Study Assessing the Safety and Immune Response of the mRNA-CR-04 Vaccine Targeting SARS-CoV-2 (Omicron BA.5) in Adults Aged 18 to 49

At a Glance

Key Highlights

• mRNA-CR-04 vaccine doses (3 to 100 µg) were generally well tolerated with mostly mild to moderate and transient adverse events.
• Robust neutralizing antibody responses were induced against the BA.5 variant and cross-neutralization against wild-type SARS-CoV-2 (D614G) was observed.
• Neutralizing antibody titers waned by 6 months post-vaccination but remained above baseline levels.

Guideline-Based Recommendations

Diagnosis

• Not applicable; study focused on vaccine safety and immunogenicity rather than diagnosis.

Management

• Administer mRNA-CR-04 vaccine as a single booster dose at doses ranging from 3 to 100 µg in adults aged 18–49 years.
• Monitor for solicited adverse events, which are expected to be mostly mild to moderate and transient.

Monitoring & Follow-up

• Observe participants for at least 60 minutes post-vaccination for immediate adverse reactions.
• Assess solicited and unsolicited adverse events up to 31 days post-vaccination.
• Evaluate neutralizing antibody titers up to 6 months post-vaccination to monitor immune response durability.

Risks

• Grade 3 reactogenicity observed only at the highest dose (100 µg) in a minority of participants (16.7%).
• No safety concerns causally related to mRNA-CR-04 vaccine identified.
• Serious adverse events occurred but were deemed unrelated to the vaccine.

Patient & Prescribing Data

Healthy or medically stable adults aged 18 to 49 years previously vaccinated with mRNA COVID-19 vaccines.

Single-dose mRNA-CR-04 vaccine induces robust neutralizing antibody responses with acceptable safety profile; immune response magnitude increases with dose.

Clinical Best Practices

• Use staggered sentinel dosing with safety review before escalating doses in early-phase vaccine trials.
• Employ randomized, placebo-controlled, observer-blind design to assess vaccine safety and immunogenicity.
• Include multiple dose levels to identify optimal balance between immunogenicity and reactogenicity.
• Monitor both solicited and unsolicited adverse events with extended follow-up to capture safety and immune durability.

References

• ClinicalTrials.gov NCT05972993